Efficacy of GCN2 inhibition by a novel small molecule AP030 in acute leukemia.

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Abstract 618: Preclinical assessment of APL-030, a selective and orally bioavailable inhibitor of the integrated stress response regulator GCN2 with activity against acute myeloid leukemia2024 · 2 citations
2. 2Nonclinical evaluation of APL-4098, a novel GCN2 kinase inhibitor, reveals potent anti-leukemic effects through mitochondrial stress induction and synergy with venetoclax, targeting AML blasts and LSCs2025
3. 3A novel potent and selective GCN2 inhibitor, APL-4098, has anti-leukemic activity through dysregulation of mitochondrial function2026 · 2 citations
4. 4Characterisation of Small-Molecule GCN2 Modulators2025
5. 5GCN2 Activation Promotes PD-L1 Expression and Survival of RPMI-8226 Multiple Myeloma Cells: An In Vitro Study Under Arginine Deprivation2026